Viatris Pipeline Progress Includes Eylea, Botox Biosimilars
Executive Summary
In its first sales and earnings call, Viatris management updated investors on the development of some key complex generics and biosimilars.
You may also be interested in...
Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.
Biocon And Viatris Scoop EU Insulin Aspart Approval
Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.
Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus
Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.